^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lucentis (ranibizumab)

    i
    Other names: RG-3645, RG 3645, rhuFabV2, RG3645
    Associations

    News

    Trials
    Company:
    China Medical System, Novartis, Roche, Santen
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Associations

    News

    Trials
    7d
    BURGUNDY: Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P1/2, N=177, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2028 --> Aug 2026 | Trial primary completion date: Feb 2027 --> Aug 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    Lucentis (ranibizumab)
    28d
    VOYAGER: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (clinicaltrials.gov)
    P=N/A, N=6000, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2026 --> Mar 2027
    Enrollment closed • Trial primary completion date • Real-world evidence
    |
    Lucentis (ranibizumab)
    1m
    A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss (clinicaltrials.gov)
    P3, N=351, Completed, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    Lucentis (ranibizumab)
    1m
    A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Tasly Pharmaceutical Group Co., Ltd
    New P3 trial
    |
    Lucentis (ranibizumab)
    1m
    Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration (clinicaltrials.gov)
    P3, N=488, Completed, Bio-Thera Solutions | Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion • Trial primary completion date
    |
    Lucentis (ranibizumab)
    2ms
    Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Lucentis (ranibizumab) • Simponi (golimumab)
    2ms
    M-VIVA: Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting (clinicaltrials.gov)
    P=N/A, N=117, Recruiting, Singapore National Eye Centre
    New trial
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Lucentis (ranibizumab)
    2ms
    PAVILION: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (clinicaltrials.gov)
    P3, N=174, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jun 2025 --> Jan 2026
    Trial completion date
    |
    Lucentis (ranibizumab)
    2ms
    Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=561, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events • Real-world evidence
    |
    Lucentis (ranibizumab)
    2ms
    Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (clinicaltrials.gov)
    P2, N=120, Recruiting, Carmen Clapp | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PRL (Prolactin)
    |
    Lucentis (ranibizumab)
    2ms
    AAVIATE: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P2, N=140, Recruiting, AbbVie | Trial completion date: Aug 2026 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    Lucentis (ranibizumab)
    3ms
    Sightspire: A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD (clinicaltrials.gov)
    P3, N=250, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lucentis (ranibizumab)